Article Text

Download PDFPDF
TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma
  1. Glauco Baiocchi1,
  2. Fernando Luís Visoni Poliseli1,
  3. Louise De Brot2,
  4. Henrique Mantoan1,
  5. Beatriz Nunes Schiavon1,
  6. Carlos Chaves Faloppa1,
  7. Jose Vassallo2,
  8. Fernando Augusto Soares2,
  9. Isabela Werneck Cunha2
  1. 1Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil
  2. 2Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil
  1. Correspondence to Dr Glauco Baiocchi, Departamento de Ginecologia Oncológica, AC Camargo Cancer Center, Rua Antonio Prudente, 211, São Paulo 01509-010, Brazil; glbaiocchi{at}, glauco.baiocchi{at}


Aims To examine TOP2A copy number, TOP2A expression, and its prognostic value in uterine leiomyosarcoma (LMS) and other benign smooth muscle tumours.

Methods We analysed 37 patients treated for uterine LMS with immunohistochemistry for protein expression and fluorescence in situ hybridisation (FISH) for copy number. Twelve cases of leiomyoma variants (LMVs), 4 smooth muscle tumours of uncertain malignant potential (STUMP) and 23 leiomyomas (LMs) were also included.

Results Eighteen patients with LMS (48.6%) were International Federation of Gynecology and Obstetrics (FIGO) stage I, six (16.2%) were stage II, four (10.8%) were stage III, and nine (24.3%) were stage IV. Twenty-one (56.8%) patients with LMS showed high expression of TOP2A. Greater TOP2A levels were found in patients with stage ≥II disease compared with stage I and also in high mitotic index tumours (>20/10 HPF (high power field)). Eleven (36.7%) cases had abnormal TOP2A copy numbers. There was no link between TOP2A copy number and TOP2A expression. All patients with benign smooth muscle tumours had low TOP2A immunohistochemical expression and one (7.7%) patient had TOP2A amplification. TOP2A expression and TOP2A copy number had no impact on disease outcomes. Only the presence of disease outside of the uterus negatively impacted survival compared with early disease (53.4 vs 15.8 months; p<0.001).

Conclusions TOP2A is highly expressed in advanced LMS but not in non-malignant diseases. TOP2A expression does not correlate with FISH results and does not predict outcome. TOP2A levels are higher in high-mitotic index tumours and in more advanced stages of disease.

  • FISH

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.